Identification and characterization of seven new exon 11-associated splice variants of the rat μ opioid receptor gene, OPRM1.
BACKGROUND
The mouse mu opioid receptor (OPRM1) gene undergoes extensive alternative splicing at both the 3'- and 5'-ends of the gene. Previously, several C-terminal variants generated through 3' splicing have been identified in the rat OPRM1 gene. In both mice and humans 5' splicing generates a number of exon 11-containing variants. Studies in an exon 11 knockout mouse suggest the functional importance of these exon 11-associated variants in mediating the analgesic actions of a subset of mu opioids, including morphine-6β-glucuronide (M6G) and heroin, but not others such as morphine and methadone. We now have examined 5' splicing in the rat.


RESULTS
The current studies identified in the rat a homologous exon 11 and seven exon 11-associated variants, suggesting conservation of exon 11 and its associated variants among mouse, rat and human. RT-PCR revealed marked differences in the expression of these variants across several brain regions, implying region-specific mRNA processing of the exon 11-associated variants. Of the seven rat exon 11-associated variants, four encoded the identical protein as found in rMOR-1, two predicted 6 TM variants, and one, rMOR-1H2, generated a novel N-terminal variant in which a stretch of an additional 50 amino acids was present at the N-terminus of the previously established rMOR-1 sequence. When expressed in CHO cells, the presence of the additional 50 amino acids in rMOR-1H2 significantly altered agonist-induced G protein activation with little effect on opioid binding.


CONCLUSIONS
The identification of the rat exon 11 and its associated variants further demonstrated conservation of 5' splicing in OPRM1 genes among rodents and humans. The functional relevance of these exon 11 associated variants was suggested by the region-specific expression of their mRNAs and the influence of the N-terminal sequence on agonist-induced G protein coupling in the novel N-terminal variant, rMOR-1H2. The importance of the exon 11-associated variants in mice in M6G and heroin analgesia revealed in the exon 11 knockout mouse implies that these analogous rat variants may also play similar roles in rat. The complexity created by alternative splicing of the rat OPRM1 gene may provide important insights of understanding the diverse responses to the various μ opioids seen in rats.
Department of Neurology and Program in Molecular Pharmacology and Chemistry, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
Jin
J
Xu
Mingming
M
Xu
Grace C
GC
Rossi
Gavril W
GW
Pasternak
Ying-Xian
YX
Pan
D017398:Alternative Splicing / Q000235:genetics*; D000595:Amino Acid Sequence; D000818:Animals; D001483:Base Sequence; D015152:Blotting, Northern; D003001:Cloning, Molecular; D005091:Exons / Q000235:genetics*; D016244:Guanosine 5'-O-(3-Thiotriphosphate) / Q000378:metabolism; D006801:Humans; D051379:Mice; D008969:Molecular Sequence Data; D014176:Protein Biosynthesis / Q000235:genetics; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D051381:Rats; D017450:Receptors, Opioid, mu / Q000819:agonists / Q000737:chemistry / Q000235:genetics* / Q000378:metabolism; D011994:Recombinant Proteins / Q000378:metabolism; D012689:Sequence Homology, Nucleic Acid
C485765:Oprm1 protein, rat; D012333:RNA, Messenger; D017450:Receptors, Opioid, mu; D011994:Recombinant Proteins; D016244:Guanosine 5'-O-(3-Thiotriphosphate)
J Pharmacol Exp Ther. 1976 Jun;197(3):517-32
945347
Gene. 2007 Jun 15;395(1-2):98-107
17398041
Hum Mol Genet. 2009 Mar 15;18(6):1037-51
19103668
Neuroscience. 2000;100(1):141-53
10996465
Nature. 2000 Dec 7;408(6813):720-3
11130073
Eur J Neurosci. 2002 Sep;16(6):1075-82
12383236
Biochem Biophys Res Commun. 2006 May 19;343(4):1132-40
16580639
J Neurochem. 2009 Feb;108(4):962-72
19077058
J Neurochem. 2004 Nov;91(4):881-90
15525342
Mol Pharmacol. 1999 Aug;56(2):396-403
10419560
Mol Pharmacol. 1995 Jun;47(6):1180-8
7603458
Life Sci. 2002 Dec 6;72(3):269-77
12427486
Nature. 1977 Jun 9;267(5611):495-9
195217
Nature. 2000 Nov 9;408(6809):199-203
11089973
Life Sci. 1994;54(21):PL375-9
8196473
Nature. 1975 Feb 13;253(5492):563-5
1117990
FEBS Lett. 2000 Jan 28;466(2-3):337-40
10682855
J Immunol. 2003 May 15;170(10):5118-23
12734358
Neuroscience. 2005;133(1):209-20
15893644
Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):14084-9
11717463
Neuron. 1993 Nov;11(5):903-13
8240812
Proc Natl Acad Sci U S A. 2009 Mar 24;106(12):4917-22
19273844
Trends Pharmacol Sci. 1995 Jul;16(7):246-52
7667899
Neuroreport. 2000 Jun 26;11(9):1953-7
10884050
Brain Res Mol Brain Res. 2002 Dec 30;109(1-2):168-78
12531526
DNA Cell Biol. 2005 Nov;24(11):736-50
16274294
J Mol Med (Berl). 2004 Apr;82(4):250-5
14991152
Biochem Biophys Res Commun. 2003 Feb 21;301(4):1057-61
12589820
Neuroscience. 2001;106(4):833-42
11682168
Clin Neuropharmacol. 1993 Feb;16(1):1-18
8093680
Nat Neurosci. 1999 Feb;2(2):151-6
10195199
Neuropharmacology. 2004;47 Suppl 1:312-23
15464147
Gene. 2007 Feb 15;388(1-2):135-47
17156941
Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):10230-4
8234282
Brain Res. 2006 Jul 12;1099(1):33-43
16793025
FEBS Lett. 1992 Oct 26;311(3):290-4
1397330
Neuroreport. 2001 Oct 8;12(14):3069-72
11568638
Mol Pharmacol. 2005 Sep;68(3):866-75
15939800
J Comp Neurol. 2000 Apr 3;419(2):244-56
10723002
Proc Natl Acad Sci U S A. 1981 Oct;78(10):6181-5
6273857
J Biol Chem. 2003 Sep 19;278(38):36733-9
12860981
Proc Natl Acad Sci U S A. 1998 Jun 9;95(12):7157-62
9618555
Science. 1980 May 2;208(4443):514-6
6245448
Neurosci Lett. 2002 Jun 21;326(1):37-40
12052533
Mol Pharmacol. 1993 Jul;44(1):8-12
8393525
Biochem Biophys Res Commun. 2003 Sep 5;308(4):961-5
12927813
FEBS Lett. 1995 Feb 13;359(2-3):142-6
7532594
Biochem Biophys Res Commun. 2000 Feb 16;268(2):354-8
10679207
Synapse. 2004 Jan;51(1):11-8
14579421
FEBS Lett. 1994 Nov 7;354(2):213-6
7957926
Nature. 1993 Sep 9;365(6442):166-70
8396726
J Biol Chem. 1995 Mar 31;270(13):7354-8
7706278
FEBS Lett. 1995 Aug 7;369(2-3):192-6
7649256
Anal Biochem. 1987 Apr;162(1):156-9
2440339